George Reader
Interventional Cardiology · Wichita, KSNPI 1508812744
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 272 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,443 and has fallen 80.8% since, to $277 in 2023. That places this record below the midpoint for interventional cardiology clinicians in KS, where the typical reported total is $8,846.
Across 272 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$542
- Amgen$469
- AstraZeneca$409
- Merck$375
- Novartis$352
- Abbott$249
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,10899%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 48 | $542 |
| Amgen | 30 | $469 |
| AstraZeneca | 26 | $409 |
| Merck | 26 | $375 |
| Novartis | 24 | $352 |
| Abbott | 9 | $249 |
| Sanofi-aventis U.S. LLC | 15 | $200 |
| Esperion Therapeutics, Inc. | 13 | $182 |
| Amarin Pharma, Inc. | 11 | $176 |
| Pfizer | 9 | $135 |
| Regeneron Healthcare Solutions, Inc. | 6 | $120 |
| United Therapeutics Corporation | 7 | $117 |
| Alnylam Pharmaceuticals Inc. | 5 | $117 |
| Boston Scientific | 4 | $77 |
| Actelion Pharmaceuticals US, Inc. | 5 | $72 |
| Astellas Pharma US Inc | 4 | $71 |
| Lundbeck LLC | 3 | $54 |
| Kowa Pharmaceuticals America, Inc. | 4 | $51 |
| E.r. Squibb & Sons, L.L.C. | 4 | $49 |
| Boehringer Ingelheim | 3 | $48 |
| Arbor Pharmaceuticals, Inc. | 3 | $45 |
| Abiomed | 1 | $41 |
| Bardy Diagnostics, Inc. | 2 | $35 |
| Medtronic | 2 | $31 |
| Cvrx, Inc. | 2 | $30 |
| Sanofi | 1 | $19 |
| Novo Nordisk | 1 | $16 |
| Edwards Lifesciences | 1 | $15 |
| Aegerion Pharmaceuticals, Inc. | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
| Surmodics, Inc. | 1 | $7 |
How this compares
$4,129 in reported general payments places this provider in the 25th percentile of 55 interventional cardiology providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Labetalol Hcl | 23 | $480 |
| Amiodarone Hcl | 25 | $262 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 15 | $246 |
| Atorvastatin Calcium | 36 | $151 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 19 | $94 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Wichita
- Maheedhar GedelaWichita$54K
- Hussam FarhoudWichita$25K
- Christian HouraniWichita$17K
- Gaurav TyagiWichita$13K
- Ravi BajajWichita$10K
- Assem FarhatWichita$9K
- Venkata BoppanaWichita$9K
- Alaa BouladWichita$8K
- Rohma ShaikhWichita$4K
- Mohamed ElmassryWichita$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.